Published in Mod Pathol on April 08, 2016
A Prospective Study of Monitoring Immune Response in Locally Advanced Cervix Cancer | NCT03559803
Improving the efficiency of image guided brachytherapy in cervical cancer. J Contemp Brachytherapy (2016) 0.82
Human papillomavirus-driven immune deviation: challenge and novel opportunity for immunotherapy. Ther Adv Vaccines (2017) 0.75
Classical and non-classical HLA class I aberrations in primary cervical squamous- and adenocarcinomas and paired lymph node metastases. J Immunother Cancer (2016) 0.75
Expression of PD-L1 and presence of CD8-positive T cells in pre-treatment specimens of locally advanced cervical cancer. Mod Pathol (2017) 0.75
Independent prognostic role of PD-L1expression in patients with esophageal squamous cell carcinoma. Oncotarget (2017) 0.75
PD-L1 expression as poor prognostic factor in patients with non-squamous non-small cell lung cancer. Oncotarget (2017) 0.75
SHP2 negatively regulates HLA-ABC and PD-L1 expression via STAT1 phosphorylation in prostate cancer cells. Oncotarget (2017) 0.75
Immunopathogenesis of HPV-Associated Cancers and Prospects for Immunotherapy. Viruses (2017) 0.75
PD-L1/PD-1 expression and tumor-infiltrating lymphocytes in conjunctival melanoma. Oncotarget (2017) 0.75
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 52.99
Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med (2012) 13.12
Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A (2002) 12.39
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature (2014) 12.00
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature (2014) 10.49
Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res (2006) 8.21
The future of immune checkpoint therapy. Science (2015) 5.59
Programmed death ligand-1 expression in non-small cell lung cancer. Lab Invest (2013) 4.96
B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression. Clin Cancer Res (2004) 4.65
Cervical cancer. Lancet (2003) 4.05
The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors. Neoplasia (2006) 3.54
Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance. Acta Histochem (2006) 3.24
High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation. Med Oncol (2010) 3.06
Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma. Cancer Res (2013) 2.81
The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in the United States--a 24-year population-based study. Gynecol Oncol (2000) 2.76
PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy. Mol Cancer Ther (2015) 2.21
Tumor-expressed B7-H1 and B7-DC in relation to PD-1+ T-cell infiltration and survival of patients with cervical carcinoma. Clin Cancer Res (2009) 2.04
M2 macrophages induced by prostaglandin E2 and IL-6 from cervical carcinoma are switched to activated M1 macrophages by CD4+ Th1 cells. J Immunol (2011) 2.02
PD-L1 expression in small cell neuroendocrine carcinomas. Eur J Cancer (2015) 1.85
Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma. Blood (2015) 1.80
Characterization of four conventional dendritic cell subsets in human skin-draining lymph nodes in relation to T-cell activation. Blood (2011) 1.76
A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G. Eur Urol (2015) 1.73
Human leukocyte antigen class I, MHC class I chain-related molecule A, and CD8+/regulatory T-cell ratio: which variable determines survival of cervical cancer patients? Clin Cancer Res (2008) 1.54
Oncogenic mutations in cervical cancer: genomic differences between adenocarcinomas and squamous cell carcinomas of the cervix. Cancer (2013) 1.52
PD-L1 and Survival in Solid Tumors: A Meta-Analysis. PLoS One (2015) 1.45
Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell Carcinoma. Cancer Immunol Res (2015) 1.35
Intrinsic and extrinsic control of expression of the immunoregulatory molecule PD-L1 in epithelial cells and squamous cell carcinoma. Oral Oncol (2014) 1.24
Assays for predicting and monitoring responses to lung cancer immunotherapy. Cancer Biol Med (2015) 1.23
PD-L1 Expression in Clear Cell Renal Cell Carcinoma: An Analysis of Nephrectomy and Sites of Metastases. J Cancer (2014) 1.20
Chemoradiotherapy for cervical cancer. Eur J Cancer (2002) 1.19
PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma. Lung Cancer (2015) 1.17
Prognostic model for survival in patients with early stage cervical cancer. Cancer (2010) 1.16
Prognostic significance of programmed cell death 1 (PD-1) or PD-1 ligand 1 (PD-L1) Expression in epithelial-originated cancer: a meta-analysis. Medicine (Baltimore) (2015) 1.14
Susceptibility to cervical cancer: an overview. Gynecol Oncol (2012) 1.07
High and interrelated rates of PD-L1+CD14+ antigen-presenting cells and regulatory T cells mark the microenvironment of metastatic lymph nodes from patients with cervical cancer. Cancer Immunol Res (2014) 1.05
Tumor-infiltrating CD14-positive myeloid cells and CD8-positive T-cells prolong survival in patients with cervical carcinoma. Int J Cancer (2013) 1.05
Increased expression of programmed death (PD)-1 and its ligand PD-L1 correlates with impaired cell-mediated immunity in high-risk human papillomavirus-related cervical intraepithelial neoplasia. Immunology (2013) 1.04
Radical hysterectomy for stage IIB cervical cancer: a review. Int J Gynecol Cancer (2005) 1.04
Is there really a difference in survival of women with squamous cell carcinoma, adenocarcinoma, and adenosquamous cell carcinoma of the cervix? Cancer (1995) 1.03
Immune checkpoint modulation for non-small cell lung cancer. Clin Cancer Res (2015) 0.97
Functional characterization of a STAT3-dependent dendritic cell-derived CD14(+) cell population arising upon IL-10-driven maturation. Oncoimmunology (2013) 0.92
Enhanced expression of PD L1 in cervical intraepithelial neoplasia and cervical cancers. Mod Pathol (2015) 0.91
Characterization of the in vivo immune network of IDO, tryptophan metabolism, PD-L1, and CTLA-4 in circulating immune cells in melanoma. Oncoimmunology (2015) 0.89
The prognostic significance of PD-L1 in bladder cancer. Oncol Rep (2015) 0.89
Nodal metastasis in cervical cancer occurs in clearly delineated fields of immune suppression in the pelvic lymph catchment area. Oncotarget (2015) 0.87
Dendritic Cell Plasticity in Tumor-Conditioned Skin: CD14(+) Cells at the Cross-Roads of Immune Activation and Suppression. Front Immunol (2013) 0.87
HLA-E expression in cervical adenocarcinomas: association with improved long-term survival. J Transl Med (2012) 0.85
FoxP3(+) and IL-17(+) cells are correlated with improved prognosis in cervical adenocarcinoma. Cancer Immunol Immunother (2015) 0.85
Role of IL-12p40 in cervical carcinoma. Br J Cancer (2012) 0.84
Correlations between immune response and vascularization qRT-PCR gene expression clusters in squamous cervical cancer. Mol Cancer (2015) 0.83
Comparison of outcomes between squamous cell carcinoma and adenocarcinoma in patients with surgically treated stage I-II cervical cancer. Mol Clin Oncol (2014) 0.82
Prognostic value of programed death ligand 1 in patients with solid tumors: A meta-analysis. J Cancer Res Ther (2015) 0.82
The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment. Oncologist (2015) 0.81
Precise Classification of Cervical Carcinomas Combined with Somatic Mutation Profiling Contributes to Predicting Disease Outcome. PLoS One (2015) 0.80
The tumor area occupied by Tbet+ cells in deeply invading cervical cancer predicts clinical outcome. J Transl Med (2015) 0.79
High levels of soluble MICA are significantly related to increased disease-free and disease-specific survival in patients with cervical adenocarcinoma. Tissue Antigens (2015) 0.78